OncologyOnline.net

Oncology Xagena

Search results for "Atezolizumab"

Early results from a pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A ) in people with locally advanced or metastatic urothelial car ...


Positive results from two phase II studies that evaluated the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A ) in people with advanced non-small cell lung cancer ( NSCLC ) we ...


In the large pivotal phase II study, BIRCH, the investigational cancer immunotherapy Atezolizumab ( MPDL3280A; anti-PD-L1 ) met its primary endpoint and shrank tumors ( objective response rate; ORR ) ...


Updated results from the pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy Atezolizumab ( MPDL3280A ) in people with locally advanced or metastatic urothelial carcinoma ...


Patients with metastatic urothelial carcinoma have few treatment options after failure of Platinum-based chemotherapy. In this trial, researchers have assessed treatment with Atezolizumab, an engineer ...